Results
104
Companys with strong funding and high growth potential
104 companies
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
BOVN.F | SEK 4.70 | 0% | n/a | SEK 2.7b | SEK 12.58 | PS9.2x | E62.0% | n/a | Pharmaceuticals & Biotech | ||
0RV2 | SEK 159.40 | -6.2% | -43.3% | SEK 14.1b | SEK 289.33 | PS47.2x | E98.4% | 0% | Pharmaceuticals & Biotech | ||
IMGN | US$31.23 | 6.6% | 617.9% | US$8.4b | US$28.95 | PS29.1x | E45.8% | n/a | Pharmaceuticals & Biotech | ||
SGEN | US$228.74 | 4.5% | 76.5% | US$43.2b | US$228.91 | PS18.8x | E71.8% | n/a | Pharmaceuticals & Biotech | ||
0A8R | US$228.95 | 4.6% | 81.1% | US$43.2b | US$229.12 | PS18.8x | E71.8% | n/a | Pharmaceuticals & Biotech | ||
ARGX | €536.11 | 0.6% | 9.0% | €28.6b | €572.01 | PS19.3x | E58.4% | n/a | Pharmaceuticals & Biotech | ||
IVVD | US$1.15 | -4.2% | -32.4% | US$124.2m | US$8.65 | PS60.7x | E70.4% | n/a | Pharmaceuticals & Biotech | ||
0A8K | US$31.24 | 6.4% | 658.3% | US$8.4b | US$29.16 | PS29.1x | E45.9% | n/a | Pharmaceuticals & Biotech | ||
ARDX | US$6.65 | 8.5% | 63.0% | US$1.5b | US$11.28 | PS7.5x | E66.3% | n/a | Pharmaceuticals & Biotech | ||
BIOABS | SEK 173.90 | 0% | -37.8% | SEK 14.1b | SEK 315.65 | PS47.2x | E98.4% | 0% | Pharmaceuticals & Biotech | ||
ARGN.F | €525.60 | 0% | n/a | €28.6b | €560.79 | PS19.3x | E58.4% | n/a | Pharmaceuticals & Biotech | ||
BRCT.F | SEK 16.04 | -5.0% | -37.1% | SEK 14.1b | SEK 28.54 | PS48.2x | E98.4% | 0% | Pharmaceuticals & Biotech | ||
AKES.F | HK$8.73 | 2.9% | n/a | HK$58.4b | HK$8.52 | PS28.1x | E54.5% | n/a | Pharmaceuticals & Biotech | ||
0QW0 | €475.22 | -1.1% | 3.2% | €28.6b | €507.04 | PS19.3x | E58.4% | n/a | Pharmaceuticals & Biotech | ||
ARGXB | €481.80 | 0% | 4.4% | €28.6b | €514.06 | PS19.3x | E58.4% | n/a | Pharmaceuticals & Biotech | ||
BPMC | US$92.55 | 0.9% | 84.3% | US$5.9b | US$127.35 | PS16.2x | E67.4% | n/a | Pharmaceuticals & Biotech | ||
0HOJ | US$93.83 | 1.3% | 87.4% | US$5.9b | US$129.11 | PS16.2x | E67.4% | n/a | Pharmaceuticals & Biotech | ||
ISEE | US$39.95 | 0.9% | 236.3% | US$5.5b | US$40.00 | PB11.6x | E59.0% | n/a | Pharmaceuticals & Biotech | ||
IVBI.Y | HK$22.00 | 0% | n/a | HK$76.0b | HK$27.68 | PS9.2x | E59.4% | n/a | Pharmaceuticals & Biotech | ||
ENSC | US$0.29 | -10.6% | -79.1% | US$3.0m | US$8.60 | PS2.2x | E99.1% | n/a | Pharmaceuticals & Biotech | ||
MDGL | US$212.43 | -9.0% | 45.5% | US$4.6b | US$360.57 | PS315.1x | E68.1% | n/a | Pharmaceuticals & Biotech | ||
URGN | US$12.90 | -4.7% | -7.9% | US$537.0m | US$43.10 | PS6.4x | E55.1% | n/a | Pharmaceuticals & Biotech | ||
CAPR | US$9.95 | 97.0% | 190.9% | US$353.0m | US$31.00 | PS12.9x | E68.7% | n/a | Pharmaceuticals & Biotech | ||
TSVT | US$4.93 | -2.4% | 25.8% | US$245.1m | US$8.25 | PS5.8x | E76.5% | n/a | Pharmaceuticals & Biotech |